

Moving on from GWAS: Functional Studies on the *G6PC2* Gene Implicated in the Regulation of Fasting Blood Glucose

Richard M. O'Brien

Published online: 22 October 2013
© Springer Science+Business Media New York 2013

Abstract Genome-wide association studies (GWAS) have shown that single-nucleotide polymorphisms (SNPs) in *G6PC2* are the most important common determinants of variations in fasting blood glucose (FBG) levels. Molecular studies examining the functional impact of these SNPs on *G6PC2* gene transcription and splicing suggest that they affect FBG by directly modulating *G6PC2* expression. This conclusion is supported by studies on *G6pc2* knockout (KO) mice showing that *G6pc2* represents a negative regulator of basal glucose-stimulated insulin secretion that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux and opposing the action of glucokinase. Suppression of *G6PC2* activity might, therefore, represent a novel therapy for lowering FBG and the risk of cardiovascular-associated mortality. GWAS and *G6pc2* KO mouse studies also suggest that *G6PC2* affects other aspects of beta cell function. The evolutionary benefit conferred by *G6PC2* remains unclear, but it is unlikely to be related to its ability to modulate FBG.

Keywords Islet · Glucose · Glucose-6-phosphatase · Insulin · Secretion · Mouse · Genome-wide association studies · GWAS · *G6PC2* gene · Fasting blood glucose · Functional studies

R. M. O'Brien
Department of Molecular Physiology and Biophysics,
Vanderbilt University School of Medicine,
Nashville, TN 37232, USA

R. M. O'Brien (✉)
Department of Molecular Physiology and Biophysics,
Vanderbilt University School of Medicine, 8415 MRB IV, 2213
Garland Ave, Nashville, TN 37232-0615, USA
e-mail: richard.obrien@vanderbilt.edu

Introduction

Over the past 5 years, through the power of genome-wide association studies (GWAS), there has been an explosion in our knowledge with respect to the identity of the genes that confer enhanced risk for the development of type 2 diabetes; over 60 loci have been linked to type 2 diabetes risk [1, 2]. GWAS data have also provided insight into the genes controlling fasting blood glucose (FBG) levels [3, 4] and glycated hemoglobin A1C (HbA1c) levels [5], as well as the genes associated with increased risk for the development of obesity [6]. Elevated FBG, HbA1c, and body mass are all important traits that are correlated with the risk of developing type 2 diabetes [7–10] and cardiovascular-associated mortality (CAM) [11–13], although, as will be discussed later, the precise relationships between FBG and type 2 diabetes [14•] and between FBG and CAM [15] are still under investigation.

At this point, multiple investigators are performing follow-up studies on the genes implicated by GWAS in an effort to understand how particular genes contribute to disease risk. This is a difficult proposition because, in many instances, the single nucleotide polymorphisms (SNPs) that have been linked to disease risk fall in intergenic regions. As such, identifying the disease-related gene(s) associated with these SNPs is a significant challenge. In some cases, these intergenic SNPs may impact the function of transcriptional control structures, such as enhancers and silencers [16], such that the genes whose expression are affected may be located a considerable distance from the SNP, although in the literature, the nearest gene is often assumed to be the likely candidate.

In relation to the GWAS data for type 2 diabetes, several of the disease-associated SNPs fall within specific genes [1]. Some of these genes had already been implicated by other genetic approaches to disease risk (*PPARG*, *KCNJ11*, *TCF7L2*) or had already been shown, or were suspected to have, a role in metabolism (*HNF1B*), obesity (*FTO*), or beta

cell biology (*SLC30A8*) through molecular studies. Several excellent recent reviews have highlighted the progress made in understanding the molecular and physiological mechanisms whereby the *FTO*, *SLC30A8*, and *TCF7L2* genes contribute to disease risk [17–20]. However, for most of the genes linked by GWAS to type 2 diabetes, the mechanisms by which the encoded proteins modulate disease risk remain unclear [1].

With respect to the genes linked to variations in FBG, multiple GWAS have shown that the *G6PC2* locus harbors the strongest common genetic determinant of FBG levels in terms of significance and effect size with a common SNP, rs560887, explaining ~1 % of the total variance in FBG [3, 4, 21–26]. Common variants in the *GCK* gene, which encodes glucokinase, have also been linked to variations in FBG, but the influence of these common *GCK* variants on FBG is less than that of the common variants in *G6PC2* [3]. This observation highlights a critical point—namely, that the magnitude of the effect of common gene variants identified through GWAS does not necessarily correlate with the importance of the gene in relation to the parameter under investigation. With respect to *G6PC2* and *GCK*, deletion of the *G6pc2* gene in mice has a mild metabolic phenotype [27, 28•] and rare mutations in *G6PC2* are not a cause of monogenic forms of diabetes [29]. In contrast, deletion of the *Gck* gene in mice is lethal [30], and rare heterozygous inactivating mutations in *GCK* are a cause of maturity-onset diabetes of the young, which is characterized by mild fasting hyperglycemia, whereas homozygous inactivating glucokinase mutations result in permanent neonatal diabetes mellitus, which is characterized by severe hyperglycemia [31]. In contrast, glucokinase activating mutations result in hyperinsulinemia leading to hypoglycemia [31]. These rare *GCK* mutations have provided fascinating molecular insights into the function of glucokinase [31] and, along with mouse models of *Gck* overexpression [32] and tissue-specific deletion [30, 33], have contributed greatly to the recognition that glucokinase is the pancreatic islet beta cell glucose sensor [34]. Far less is known about the *G6PC2* gene, which is the focus of this review.

***G6PC2* Encodes a Glucose-6-Phosphatase Catalytic Subunit**

Glucose-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosphate [35–39]. It exists as a multicomponent system located in the endoplasmic reticulum and is made up of several integral membrane proteins—namely, a catalytic subunit (G6PC), a glucose transporter, and a G6P/inorganic phosphate antiporter [35–39]. Three G6PC isoforms have been identified, designated G6PC, G6PC2, and G6PC3 [39]. Each isoform is encoded by a separate gene with a distinct pattern of tissue-specific expression [39]. G6PC2 was originally named IGRP, which

stands for islet-specific glucose-6-phosphatase catalytic subunit related protein [40, 41]. The *G6PC2* gene is expressed exclusively in pancreatic islet beta cells [42]. G6PC2 is a major autoantigen in both mouse [43–45] and human [46, 47] type 1 diabetes, but interestingly, GWAS data have not linked *G6PC2* SNPs to type 1 diabetes risk [48].

Correlation Between GWAS and Knockout Mouse Data with Respect to the Regulation of FBG by *G6PC2*

Taneera et al. [49] have suggested that rs560887, which is located in the third intron of *G6PC2*, acts in *trans* to modulate the expression of multiple other genes, but more recent molecular studies [50], which will be described later, have shown that the “A” allele of rs560887, which is associated with reduced FBG, leads directly to a reduction in *G6PC2* expression. As such, these molecular data are consistent with the ~15 % decrease in FBG observed following a global knockout (KO) of *G6pc2* in mice [27, 28•]. This decrease in FBG is observed when *G6pc2* KO mice are studied on a mixed [27] or pure C57BL/6J [28•] genetic background. These mouse data strongly support the hypothesis that genetic variation within the *G6PC2* gene, rather than surrounding genes, directly contributes to variations in FBG in humans.

The Mechanism of FBG Regulation by *G6PC2*

A comparison of glucose-6-phosphatase activity in islets isolated from wild-type and *G6pc2* KO mice indicates that activity is abolished in the latter [28•]. These data led to the simple hypothesis that *G6pc2* acts as a negative regulator of basal glucose-stimulated insulin secretion (GSIS) by hydrolyzing G6P and, thereby, opposing the action of the glucose sensor, glucokinase [51, 52] (Fig. 1). This glucokinase/*G6pc2* futile substrate cycle is predicted to reduce glycolytic flux and, hence, insulin secretion [28•]. Consistent with this model and human GWAS data, a reduction in *G6pc2* expression results in a leftward shift in the dose response curve for GSIS, explaining why, under fasting conditions, blood glucose levels are reduced [28•].

Do GWAS and Knockout Mouse Data Resolve the Historical Controversy Over Islet Glucose-6-Phosphatase?

Historically, the role of glucose-6-phosphatase activity in pancreatic islets has been highly controversial. Initially, there was debate over whether such activity even existed in islets, although, over time, the majority of studies found that activity was detectable, but at a lower level than that found in the liver




Fig. 1 G6PC2 regulates glucose-stimulated insulin secretion (GSIS) by opposing the action of glucokinase. The model shows the best-characterized pathway for GSIS, although studies on potassium channel mutations indicate that other pathways clearly contribute [96]. The glucose-6-phosphate (G6P) transporter (G6PT) and inorganic phosphate transporter are shown in the same color to indicate the fact that G6PT is actually a G6P:Pi antiporter [97]. The model proposes that G6PC2 regulates GSIS by opposing the action of glucokinase, but it also suggests that G6PC2 might

modulate islet calcium metabolism through its ability to promote the generation of inorganic phosphate in the endoplasmic reticulum lumen, resulting in the retention of calcium [77]. (Modified from Pound LD, Oeser JK, O'Brien TP, Wang Y, Faulman CJ, Dadi PK, Jacobson DA, Hutton JC, McGuinness OP, Shiota M, O'Brien RM: G6PC2: A Negative Regulator of Basal Glucose-Stimulated Insulin Secretion. *Diabetes* 2013;62:1547–1556. Adapted with permission) [28•]

[36, 40, 53–56]. However, the harder issue to resolve is whether the level of activity is enough to affect GSIS and, therefore, be of physiological significance. This question has been investigated by several groups. Sweet et al. [56] concluded that, while glucose-6-phosphatase activity is present in rat islets, the level of activity is not enough to result in sufficient G6P hydrolysis so as to affect GSIS. However, the relevance of these rat islet data to the human GWAS data is unclear, because, in contrast to all other vertebrate species examined (see <http://genome.ucsc.edu/>), *G6PC2* is a pseudogene in rats [57].

The observations of Sweet et al. [56] and the absence of G6PC2 in rats raise the question as to what benefit islet glucose-6-phosphatase activity confers to mice and humans that is dispensable to rats. However, three observations suggest that the premise of this question is not well founded. First, rat islets express low levels of the *G6PC* isoform, whereas microarray data show no expression of *G6pc* or *G6pc3* in mouse islets (unpublished data). *G6PC* is predominantly expressed in the liver and kidney, where it catalyzes the final step in the gluconeogenic and glycogenolytic pathways [35–39], but in various rat models associated with impaired glucose tolerance, *G6PC* expression is induced [58–60]. Second, Pedersen et al. [61] have demonstrated that the rat *G6PC* promoter is activated strongly by glucose, much more so than the mouse or human *G6PC* promoters. This implies that the estimates of G6P hydrolysis in rat islets will be very dependent on the glucose concentration in the culture medium and, hence, the level of induction of *G6PC*. Third, G6PC is ~20-fold more active than G6PC2 [62], such that much less G6PC

is required in rat islets to catalyze an equivalent rate of G6P hydrolysis as observed in mouse islets. It therefore appears that G6PC may play the same role in rat islets as G6PC2 does in human and mouse islets.

Several groups have also examined G6P hydrolysis in mouse, rather than rat, islets. One early study suggested that even though glucose-6-phosphatase activity is present in mouse islets, G6P hydrolysis does not occur [63]. This counterintuitive conclusion was challenged by later studies, which showed that the measurement of G6P hydrolysis within islets is critically dependent on experimental conditions [64, 65]. The more recent GWAS and *G6pc2* KO mouse data described above, especially the demonstration that *G6pc2* accounts for the low glucose-6-phosphatase enzyme activity detected in mouse islets [28•], would seem to resolve the historical controversy over the importance of glucose-6-phosphatase activity in islets. However, two caveats remain.

The first caveat relates to the fact that estimates of glucose cycling in mouse pancreatic islets are very low [66]. However, these estimates of glucose cycling were generated using radioisotopes, and the methodology involved is associated with a number of assumptions [64, 65]. To avoid these assumptions, it will be essential to reassess the level of glucose cycling in pancreatic islets using more recently developed stable isotope methodology [67]. If the rates of glucose cycling calculated using this technology are greater than previously estimated using radioisotopes, this would support the hypothesis that G6PC2 directly influences GSIS through its ability to hydrolyze G6P. Importantly, because the glucose-6-phosphatase activity of G6PC2 is ~20-fold lower than that of

G6PC [28•, 62], it heightens the concern that G6PC2 may be influencing GSIS through a mechanism independent of its ability to hydrolyze G6P. Indeed, all three G6PC isoforms possess a phosphatidic acid phosphatase domain [68], raising the possibility that they may also have lipid substrates.

Human GWAS Data Provide Novel Insights into the Influence of G6PC2 on GSIS

The second caveat concerning the function of G6PC2 in pancreatic islets relates to the unexpected effects of altered *G6PC2* expression on insulin secretion during glucose tolerance tests. This issue was initially uncovered through the analysis of GWAS data, rather than the analysis of *G6pc2* KO mice. This provides an interesting example of how GWAS data not only can provide insight into genes linked to the initial parameter under investigation, but also can provide insight into other functions of the genes identified. As was mentioned above, a reduction in *G6pc2* expression results in a leftward shift in the dose response curve for GSIS, explaining why, under fasting conditions, blood glucose levels are reduced [28•]. But under conditions of elevated blood glucose, this same leftward shift arising from a reduction in *G6pc2* expression should result in increased GSIS. Indeed, in perfused pancreas studies comparing pancreata from wild-type and *G6pc2* KO mice, GSIS is increased in the KO pancreata at submaximal glucose concentrations [28•]. Likewise, in isolated islet studies comparing islets from wild-type and *G6pc2* KO mice, GSIS is increased in the KO islets at submaximal glucose concentrations [28•]. This increased insulin secretion at submaximal glucose concentrations was predicted to result in improved glucose tolerance in *G6pc2* KO mice. However, neither intraperitoneal nor oral glucose tolerance tests show major differences in glucose tolerance or insulin secretion between WT and *G6pc2* KO mice over a range of glucose concentrations [28•].

These observations in *G6pc2* KO mice are consistent with earlier human GWAS data showing no association between *G6PC2* and glucose tolerance [69–72]. GWAS data also showed that *G6PC2* is not associated with variations in insulin sensitivity in humans [69–72], an observation that was confirmed in *G6pc2* KO mice [28•].

To further complicate the situation, human GWAS data show that the SNP within the *G6PC2* gene that is associated with reduced *G6PC2* expression [50] and reduced FBG [3] is actually associated with a reduction in insulin secretion during glucose tolerance tests, rather than the expected increase [69–72]. So, in humans, reduced *G6PC2* expression appears to promote glycolytic flux, leading to reduced FBG, but this enhanced flux not only fails to enhance glucose tolerance during a glucose challenge, but also is actually associated with a decrease in insulin secretion during that glucose challenge.

The data with *G6pc2* KO mice appear slightly different to the human GWAS data in that a similar reduction in insulin secretion was not observed in *G6pc2* KO mice during glucose tolerance tests [28•]. However, this may simply be due to the relatively low number of animals analyzed [28•], relative to the vast number of humans analyzed in GWAS studies [69]. Thus, mouse data are inherently noisy in that significant variations in insulin sensitivity and, hence, insulin secretion are observed even within inbred C57BL/6J mice [73]. The key consistent observation is that in both mice and humans, reduced *G6PC2* expression does not lead to an improvement in glucose tolerance.

The unexpected association between reduced *G6PC2* expression and reduced insulin secretion during glucose tolerance tests in humans has been hypothesized to indicate that either G6PC2 affects the pulsatility of insulin secretion [69] or that it affects hepatic glucose production rather than beta cell function [72]. The latter explanation appears highly unlikely, since human *G6PC2* [3, 57] and mouse *G6pc2* [39, 40] are expressed only in islets and not in liver. In contrast, a change in the pulsatility of insulin secretion and, hence, the efficacy of insulin signaling would provide an elegant explanation as to how reduced *G6PC2* expression could lead to a reduction in insulin secretion that is not associated with a counterbalancing change in glucose tolerance or insulin sensitivity [69–72].

Whether the absence of *G6pc2* in mice affects the pulsatility of insulin secretion is a key question that remains to be addressed. However, if this is the explanation for the reduced insulin secretion during glucose tolerance tests in humans, the question arises as to whether the ability of G6PC2 to influence the pulsatility of insulin secretion is dependent on its ability to hydrolyze G6P or some other function, perhaps connected with the phosphatidic acid phosphatase domain mentioned above [68]. The generation of a transgenic model in which a mutated form of *G6pc2* lacking glucose-6-phosphatase activity is expressed in the *G6pc2* KO mice might provide insight into this question. Merrins et al. [74] have elegantly shown that pulsatile insulin secretion is driven by metabolic oscillations and that the magnitude of the pulses can be amplified by raising intracellular calcium levels. This then raises the question as to whether G6PC2 might affect metabolic oscillations, intracellular calcium levels, or both. Merrins et al. [75] have recently shown that metabolic oscillations in islets are initiated at an early stage in glycolysis with the mechanism likely involving the autocatalytic feedback of fructose 1, 6-bisphosphate onto phosphofructokinase 1, with phosphofructokinase 1 being activated by its product resulting in the subsequent depletion of its substrate [76]. On the basis of these data, it would appear more likely that G6PC2 affects pulsatile insulin secretion through an action on intracellular islet calcium levels, rather than metabolic oscillations. Indeed, basal cytoplasmic calcium levels are enhanced in islets isolated from *G6pc2* KO mice [28•]. This

increase was interpreted as a secondary event resulting from the enhanced rate of glycolytic flux [28•], but, on the basis of the studies of Merrins et al. [74], if this difference was instead, at least in part, a primary consequence of *G6pc2* deletion, a difference in intracellular calcium between wild-type and *G6pc2* KO islets would be predicted to be associated with altered pulsatile insulin secretion. Indeed, G6PC2 might modulate islet calcium metabolism through its ability to promote the generation of inorganic phosphate in the endoplasmic reticulum lumen, resulting in the retention of calcium [77] (Fig. 1).

Human GWAS Data Uncover an Unexpected Connection Between G6PC2 and Body Weight

In addition to uncovering the complex relationship between *G6PC2* and glucose tolerance, human GWAS data show that *G6PC2* is also unexpectedly associated with altered body fat and BMI [69]. The “A” allele of rs560887, which is associated with reduced FBG [3] and with reduced *G6PC2* expression [50], is also associated with reduced body fat and BMI [69]. Subsequently, studies on female *G6pc2* KO mice demonstrated a reduction in body fat and body weight on both chow fed and high-fat fed diets, consistent with the human GWAS data [28•]. The reason why similar differences are not observed in male mice is unclear, but the key question is how G6PC2, which is selectively expressed in islets [3, 42], could impact body fat and body weight. There appear to be three possibilities. The first, as suggested by Li et al. [69], is that changes in body weight are secondary to altered efficacy of insulin signaling arising from altered pulsatile insulin secretion. But a second possibility is that *G6PC2* is expressed elsewhere in the body, in a tissue that can influence body weight. The obvious candidate would perhaps be the hypothalamus, given its well-established role in body weight regulation and the fact that glucokinase is also expressed there [78]. Goh et al. [79] have reported very low *G6pc2* expression in mouse hypothalamus, but only at very high template concentrations and PCR cycles. Furthermore, the gene encoding the catalytically more active G6pc3 isoform was expressed at much higher levels [79], such that the loss of barely detectable *G6pc2* expression would likely have little impact on total hypothalamic glucose-6-phosphatase activity. Of note, an analysis of multiple *G6pc2-LacZ* transgenes failed to detect hypothalamic expression [27, 80, 81]. Finally, a third possibility for explaining the connection between G6PC2 and body weight relates to the kinetics of GSIS. The same model that predicts a leftward shift in the dose response curve for GSIS following a reduction in *G6PC2* expression [28•] would predict a faster rise in plasma insulin levels as glucose levels rise following a meal. Since insulin is a satiety factor [82], the more rapid rise in plasma insulin might lead to an earlier cessation of feeding and, hence, a reduction in

food intake and body mass. Further studies in *G6pc2* KO mice should be able to address this hypothesis.

Evolution and the Function of G6PC2

An intriguing aspect of the human GWAS data discussed above is the conclusion that the absence of G6PC2 would be beneficial to several aspects of human health. In relation to FBG, it would be lowered by the absence of G6PC2, which would be predicted to reduce the risk of cardiovascular-associated mortality and type 2 diabetes (but see below). Similarly, in relation to body fat and BMI, both would be lowered by the absence of G6PC2, with the expected health benefits. Finally, the human GWAS data imply that, if G6PC2 is affecting the pulsatility of insulin secretion and, hence, the efficacy of insulin signaling, this pulsatility is actually enhanced by the absence of G6PC2, explaining the reduced insulin secretion during glucose tolerance tests [69].

Since the presence of G6PC2 has been retained through mammalian evolution, with the exception of rats, this implies that there must be beneficial effects conferred by G6PC2 that are not apparent from the human GWAS data. The health benefits conferred by reduced FBG and BMI are unlikely to be relevant to reproductive potential, since the diseases associated with elevated FBG and BMI typically occur later in life, long after individuals have passed on their genetic material to their offspring. Furthermore, such diseases are prevalent only in the modern world and would not even have been a factor during the course of evolution.

The biological benefit(s) conferred by the presence of G6PC2 are currently unknown, but one possibility is that *G6PC2* expression or G6PC2 enzyme activity is activated under specific physiological conditions. This would have the effect of shifting the dose response curve for GSIS to the right, resulting in reduced insulin secretion (Fig. 2). A number of studies have suggested that the activity of hepatic G6PC is altered by insulin signaling [83], although, because the mechanisms involved are unknown, it is unclear whether the same signaling pathway might regulate G6PC2 enzyme activity. Similarly, while multiple transcription factors that contribute to the islet beta-cell-specific expression of *G6PC2* have been identified [39], there is currently no evidence that *G6PC2* expression is modulated *in vivo* under different physiological conditions. Nonetheless, there is circumstantial data to support the potential impact of altered *G6PC2* expression. First, in various rat models associated with impaired glucose tolerance, *G6PC* expression is induced such that G6P hydrolysis would be elevated and GSIS blunted [58–60]. This induction may play a protective role against excessive stimulation of the beta cells, which is a concern given their susceptibility to ER [84] and oxidative stress [85]. Second, experiments in which *G6PC* was overexpressed in pancreatic islet beta-cell-




Fig. 2 Elevated *G6PC2* expression or enzyme activity would alter the sensitivity of glucose-stimulated insulin secretion (GSIS). The evolutionary function of *G6PC2* is unknown but is unlikely to be related to the control of FBG. The model speculates that under specific physiological conditions, *G6PC2* expression or enzyme activity is elevated, changing the sensitivity of GSIS. This model is consistent with the observations that a reduction in *G6PC2* expression [28•] or *Gck* overexpression [98, 99] augments glycolytic flux and causes a leftward shift in the dose response curve for GSIS

derived cell lines using adenovirus [86] or stable transfection [87] have directly demonstrated that altered expression of this single gene is sufficient to inhibit insulin secretion.

The Relationship Between *G6PC2*, FBG, and Type 2 Diabetes Risk

Since *G6PC2* is associated with variations in FBG and HbA1c [3, 4, 21–26] and because the accepted dogma is that elevated FBG and HbA1c are associated with an increased risk for the development of type 2 diabetes [7–9], one would logically have expected that *G6PC2* would also be associated with increased risk for the development of type 2 diabetes. Indeed, studies on Chinese individuals have shown such an association [24, 25], although the sample sizes used in these studies were relatively small. Other studies, with large sample sizes, have shown that in European populations, *G6PC2* is linked to variations in FBG, but not risk for the development of type 2 diabetes [22, 23]. In contrast, a recent meta-analysis contradicted these conclusions and described an association between *G6PC2* and type 2 diabetes risk in Caucasians but not Asians [88]. Adding to the confusion, this potential discordance in the connection between *G6PC2*, FBG, and type 2 diabetes risk does not apply to other genes that have been linked to variations in FBG. For example, variations in *GCK* are linked to both FBG and type 2 diabetes risk [23].

A study by Abdul-Ghani et al. [14•] provides a potentially elegant resolution to this paradox. They have reported that the 1-h glucose level in a glucose tolerance test is a better predictor of type 2 diabetes risk than FBG, such that, after correcting for this variable, the association between FBG levels and type 2 diabetes risk is lost. The authors suggest that the apparent correlation between elevated FBG and type 2 diabetes risk is

not due to the increase in FBG per se but is due, instead, to the correlation between FBG and 1-h glycemia [14•]. On the basis of the observations of Abdul-Ghani et al. [14•], one would predict that variations in *GCK* would affect both 1-h glucose levels in a glucose tolerance test, in addition to FBG, whereas variations in *G6PC2* would affect only the latter (Fig. 3). Indeed, the rs1799884 *GCK* variant is associated with higher 1-h glucose levels [89]. In some populations [89], although not in others [69], this variant is also associated with higher 2-h glucose levels. In contrast, the rs560887 *G6PC2* variant is not associated with altered glucose tolerance [69–72]. The observations of Abdul-Ghani et al. [14•] also lead to the conclusion that the observed decrease in *G6PC2* expression in islets from donors with type 2 diabetes [49] is likely to be a secondary event—specifically, a response to the diabetic environment—rather than a causative event that contributes to the development of type 2 diabetes. Thus, on the basis of *G6pc2* KO mouse data [27, 28•], a decrease in *G6PC2* expression would lead to enhanced insulin secretion, which would make sense in terms of a compensatory attempt by unhealthy islets to maintain insulin secretion.

As is described below, the rs560887 *G6PC2* variant linked by GWAS to FBG, but not to type 2 diabetes risk, is predicted to have only a small effect on *G6PC2* expression [50]. However, even though small changes in *G6PC2* expression are not associated by GWAS with the risk for type 2 diabetes, this would not exclude the possibility that rare variants that markedly elevate *G6PC2* expression or increase activity may be associated with altered risk for type 2 diabetes.




Fig. 3 Variations in *GCK* but not *G6PC2* affect type 2 diabetes risk. Data from genome-wide association studies show that single-nucleotide polymorphisms (SNPs) in both *G6PC2* and *GCK* are associated variations in fasting blood glucose (FBG) but only SNPs in *GCK* are associated with type 2 diabetes risk. The model proposes that this observation is explained by the fact that SNPs in *GCK* are associated variations in 1-h glucose levels during a glucose tolerance test, whereas SNPs in *G6PC2* are not. This concept is based on the studies of Abdul-Ghani et al. [14•], who showed that the 1-h glucose level in a glucose tolerance test is a better predictor of type 2 diabetes risk than FBG, such that, after correcting for this variable, the association between FBG levels and type 2 diabetes risk is lost

Functional Analysis of SNPs That Modulate *G6PC2* Splicing and Gene Transcription

Several studies have examined the molecular effects of SNPs on *G6PC2* splicing and gene transcription. Two SNPs in the *G6PC2* promoter, rs13431652 and rs2232316, were shown to affect *G6PC2* fusion gene expression by modulating NF- κ B and Foxa2 binding, respectively [50, 90]. In addition, two SNPs in the third *G6PC2* intron, rs560887 and rs2232321, were shown to affect *G6PC2* RNA splicing [50]—likely, by modulating the strength of a branch point sequence, a key element in RNA splicing [91, 92]. The *in vitro* and *in situ* molecular data suggest that all four SNPs are potentially causative, since the allele that results in elevated *G6PC2* expression is associated with elevated FBG [50, 90]. In contrast, for another *G6PC2* promoter SNP, rs573225, that also affects *G6PC2* fusion gene expression by modulating Foxa2 binding, the allele that results in elevated *G6PC2* expression is associated with reduced FBG [50, 90], suggesting that rs573225 is a functional SNP that opposes the action of causative SNPs on *G6PC2* expression [50, 90], a conclusion that contrasts with an earlier study [93].

Challenges in the Identification of Causative *G6PC2* SNPs

There are several key limitations in the analysis of *G6PC2* causative SNPs. First, because these SNPs are in high linkage disequilibrium, it is difficult to definitely determine whether one or all of these SNPs are truly causative [50, 90]. Second, because the *G6PC2* gene is expressed only in pancreatic islet beta cells and because the effects of these SNPs are subtle, the lack of sufficient human samples has limited the ability to correlate genotypes with endogenous *G6PC2* expression. Finally, multiple caveats are associated with analyzing *G6PC2* promoter SNPs using fusion genes in islet-derived cell lines [50, 90]. Furthermore, most of these cell lines are derived from rodent islets, and recent studies suggest the existence of significant differences between rodent and human islets [94].

Conclusions and Future Directions

The GWAS and molecular studies described above strongly suggest that *G6PC2* modulates FBG by hydrolyzing G6P, thereby opposing the action of the beta cell glucose sensor, glucokinase. However, these studies suggest that *G6PC2* has other unexplained effects on islet beta cell function that merit further investigation. The evolutionary benefit conferred by *G6PC2* remains unclear, but it is unlikely to be related to its ability to modulate FBG. The identification of rare SNPs that markedly affect *G6PC2* enzyme activity and the analysis of the biological impact of these SNPs might provide further

insight into *G6PC2* function, as have similar studies with glucokinase. Finally, because *G6PC2* opposes the action of glucokinase, suppression of *G6PC2* activity might represent a novel therapy to lower FBG and HbA1c levels and, hence, the risk of CAM. It is noteworthy that the alternate strategy, the use of GCK activators, has shown promise with several compounds currently in clinical trials [52, 95].

Acknowledgments I would like to thank Les Satin (University of Michigan) for helpful comments on the mechanism of pulsatile insulin secretion. Research in the laboratory of R.O'B. was supported by NIH grant DK92589. This review is dedicated to the memory of my long-time colleague and friend, John C. Hutton.

Compliance with Ethics Guidelines

Conflict of Interest Richard M. O'Brien declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
1. Yaghoobkar H, Frayling TM. Recent progress in the use of genetics to understand links between type 2 diabetes and related metabolic traits. *Genome Biol.* 2013;14(3):203. doi:10.1186/gb-2013-14-3-203.
 2. Torres JM, Cox NJ, Philipson LH. Genome wide association studies for diabetes: perspective on results and challenges. *Pediatr Diabetes.* 2013;14(2):90–6. doi:10.1111/pedi.12015.
 3. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, Cavalcanti-Proenca C, et al. A polymorphism within the *G6PC2* gene is associated with fasting plasma glucose levels. *Science.* 2008;320(5879):1085–8.
 4. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, Silver KD, et al. Variations in the *G6PC2/ABC11* genomic region are associated with fasting glucose levels. *J Clin Invest.* 2008;118:2620–8.
 5. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at ten genomic loci influence hemoglobin A1C levels via glycaemic and non-glycaemic pathways. *Diabetes.* 2010;59(12):3229–39. doi:10.2337/db10-0502.
 6. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. *Endocrinology: Nature reviews;* 2013.
 7. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care.* 2006;29(7):1619–25. doi:10.2337/dc05-2525.
 8. Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. *Diabetes Care.* 2009;32 Suppl 2:S194–8. doi:10.2337/dc09-S309.

9. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Utility of hemoglobin A1c in predicting diabetes risk. *J Gen Intern Med*. 2004;19(12):1175–80. doi:10.1111/j.1525-1497.2004.40178.x.
10. Ye J. Mechanisms of insulin resistance in obesity. *Front Med*. 2013;7(1):14–24. doi:10.1007/s11684-013-0262-6.
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care*. 1999;22(2):233–40.
12. Lawes CM, Parag V, Bennett DA, Suh I, Lam TH, Whitlock G, et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. *Diabetes Care*. 2004;27(12):2836–42.
13. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. *Arterioscler Thromb Vasc Biol*. 2006;26(5):968–76. doi:10.1161/01.ATV.0000216787.85457.f3.
14. Abdul-Ghani MA, Stern MP, Lyssenko V, Tuomi T, Groop L, DeFronzo RA. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. *Diabetes Care*. 2010;33(3):557–61. doi:10.2337/dc09-1145. *This paper challenges the long held connection between FBG and type 2 diabetes risk.*
15. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215–22. doi:10.1016/S0140-6736(10)60484-9.
16. Cecchini KR, Raja Banerjee A, Kim TH. Towards a genome-wide reconstruction of cis-regulatory networks in the human genome. *Semin Cell Dev Biol*. 2009;20(7):842–8. doi:10.1016/j.semcdb.2009.06.005.
17. McMurray F, Moir L, Cox RD. From mice to humans. *Curr Diab Rep*. 2012;12(6):651–8. doi:10.1007/s11892-012-0323-2.
18. Frayling TM, Ong K. Piecing together the FTO jigsaw. *Genome Biol*. 2011;12(2):104. doi:10.1186/gb-2011-12-2-104.
19. Hansson O, Zhou Y, Renstrom E, Osmark P. Molecular function of TCF7L2: consequences of TCF7L2 splicing for molecular function and risk for type 2 diabetes. *Curr Diab Rep*. 2010;10(6):444–51. doi:10.1007/s11892-010-0149-8.
20. van de Bunt M, Gloyn AL. From genetic association to molecular mechanism. *Curr Diab Rep*. 2010;10(6):452–66. doi:10.1007/s11892-010-0150-2.
21. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. *Nat Genet*. 2008;41:77–81.
22. Reiling E, van 't Riet E, Groenewoud MJ, Welschen LM, van Hove EC, Nijpels G, et al. Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. *Diabetologia*. 2009;52:1866–70.
23. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet*. 2010;42(2):105–16.
24. Hu C, Zhang R, Wang C, Ma X, Wang C, Fang Q, et al. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. *Diabetologia*. 2009;52(3):451–6.
25. Hu C, Zhang R, Wang C, Yu W, Lu J, Ma X, et al. Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion. *PLoS One*. 2010;5(7):e11761. doi:10.1371/journal.pone.0011761.
26. Tam CH, Ho JS, Wang Y, Lee HM, Lam VK, Germer S, et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects. *PLoS One*. 2010;5(7):e11428. doi:10.1371/journal.pone.0011428.
27. Wang Y, Martin CC, Oeser JK, Sarkar S, McGuinness OP, Hutton JC, et al. Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype. *Diabetologia*. 2007;50:774–8.
28. Pound LD, Oeser JK, O'Brien TP, Wang Y, Faulman CJ, Dadi PK, et al. G6PC2: a negative regulator of basal glucose-stimulated insulin secretion. *Diabetes*. 2013;62:1547–56. doi:10.2337/db12-1067. *This study complements the related GWAS data by demonstrating that G6PC2 directly regulates FBG.*
29. Bonnefond A, Bouatia-Naji N, Simon A, Saint-Martin C, Dechaume A, de Lonlay P, et al. Mutations in G6PC2 do not contribute to monogenic forms of early infancy diabetes and beta cell dysfunction. *Diabetologia*. 2009;52(5):982–5. doi:10.1007/s00125-009-1299-6.
30. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. *Cell*. 1995;83(1):69–78.
31. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. *Hum Mutat*. 2009;30(11):1512–26. doi:10.1002/humu.21110.
32. Magnuson MA, She P, Shiota M. Gene-altered mice and metabolic flux control. *J Biol Chem*. 2003;278(35):32485–8.
33. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem*. 1999;274(1):305–15.
34. Matschinsky FM. Glucokinase, glucose homeostasis, and diabetes mellitus. *Curr Diab Rep*. 2005;5(3):171–6.
35. Mithieux G. New knowledge regarding glucose-6 phosphatase gene and protein and their roles in the regulation of glucose metabolism. *Eur J Endocrinol*. 1997;136(2):137–45.
36. Foster JD, Pederson BA, Nordlie RC. Glucose-6-phosphatase structure, regulation, and function: an update. *Proc Soc Exp Biol Med*. 1997;215(4):314–32.
37. van de Werve G, Lange A, Newgard C, Mechin MC, Li Y, Berteloot A. New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase system. *Eur J Biochem*. 2000;267(6):1533–49.
38. Van Schaftingen E, Gerin I. The glucose-6-phosphatase system. *Biochem J*. 2002;362(Pt 3):513–32.
39. Hutton JC, O'Brien RM. The glucose-6-phosphatase catalytic subunit gene family. *J Biol Chem*. 2009;284:29241–5.
40. Arden SD, Zahn T, Steegers S, Webb S, Bergman B, O'Brien RM, et al. Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. *Diabetes*. 1999;48(3):531–42.
41. Ebert DH, Bischof LJ, Streeper RS, Chapman SC, Svitek CA, Goldman JK, et al. Structure and promoter activity of an islet-specific glucose-6-phosphatase catalytic subunit-related gene. *Diabetes*. 1999;48(3):543–51.
42. Hutton JC, Eisenbarth GS. A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. *Proc Natl Acad Sci U S A*. 2003;100(15):8626–8.
43. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. *Proc Natl Acad Sci U S A*. 2003;100(14):8384–8.
44. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. *Nat Med*. 2005;11(6):645–52.
45. Mukherjee R, Waggar D, Stephens TA, Lee-Chan E, Singh B. Identification of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein: a novel beta cell autoantigen in type 1 diabetes. *J Immunol*. 2005;174(9):5306–15.

46. Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. *J Immunol*. 2006;176(5):2781–9.
47. Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. *Clin Immunol*. 2008;127(3):359–65.
48. Polychronakos C, Li Q. Understanding type 1 diabetes through genetics: advances and prospects. *Nat Rev Genet*. 2011;12(11):781–92. doi:10.1038/nrg3069.
49. Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. *Cell Metab*. 2012;16(1):122–34. doi:10.1016/j.cmet.2012.06.006.
50. Baerenwald DA, Bonnefond A, Bouatia-Naji N, Flemming BP, Umunakwe OC, Oeser JK, et al. Multiple functional polymorphisms in the *G6PC2* gene contribute to the association with higher fasting plasma glucose levels. *Diabetologia*. 2013;56(6):1306–16. doi:10.1007/s00125-013-2875-3.
51. Matschinsky FM. Banting lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. *Diabetes*. 1996;45(2):223–41.
52. Iynedjian PB. Molecular physiology of mammalian glucokinase. *Cell Mol Life Sci*. 2009;66(1):27–42.
53. Waddell ID, Burchell A. The microsomal glucose-6-phosphatase enzyme of pancreatic islets. *Biochem J*. 1988;255(2):471–6.
54. Perales MA, Sener A, Malaisse WJ. Hexose metabolism in pancreatic islets: the glucose-6-phosphatase riddle. *Mol Cell Biochem*. 1991;101(1):67–71.
55. Trandaburu T. Fine structural localization of glucose-6-phosphatase activity in the pancreatic islets of two amphibian species (*Salamandra salamandra* L. and *Rana esculenta* L.). *Acta Histochem*. 1977;59(2):246–53.
56. Sweet IR, Najafi H, Li G, Grodberg J, Matschinsky FM. Measurement and modeling of glucose-6-phosphatase in pancreatic islets. *Am J Physiol*. 1997;272(4 Pt 1):E696–711.
57. Martin CC, Bischof LJ, Bergman B, Hornbuckle LA, Hilliker C, Frigeri C, et al. Cloning and characterization of the human and rat Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein (IGRP) genes. *J Biol Chem*. 2001;276(27):25197–207.
58. Khan A, Chandramouli V, Ostenson CG, Low H, Landau BR, Efendic S. Glucose cycling in islets from healthy and diabetic rats. *Diabetes*. 1990;39(4):456–9.
59. Laybutt DR, Glandt M, Xu G, Ahn YB, Trivedi N, Bonner-Weir S, et al. Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. *J Biol Chem*. 2003;278(5):2997–3005.
60. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. *Diabetes*. 1995;44(12):1447–57.
61. Pedersen KB, Zhang P, Doumen C, Charbonnet M, Lu D, Newgard CB, et al. The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regions. *Am J Physiol Endocrinol Metab*. 2007;292(3):E788–801. doi:10.1152/ajpendo.00510.2006.
62. Petrolonis AJ, Yang Q, Tummino PJ, Fish SM, Prack AE, Jain S, et al. Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP). *J Biol Chem*. 2004;279:13976–83.
63. Ashcroft SJ, Randle PJ. Glucose-6-phosphatase activity of mouse pancreatic islets. *Nature*. 1968;219(5156):857–8.
64. Khan A, Chandramouli V, Ostenson CG, Ahren B, Schumann WC, Low H, et al. Evidence for the presence of glucose cycling in pancreatic islets of the ob/ob mouse. *J Biol Chem*. 1989;264(17):9732–3.
65. Chandramouli V, Khan A, Ostenson CG, Berggren PO, Low H, Landau BR, et al. Quantification of glucose cycling and the extent of equilibration of glucose 6-phosphate with fructose 6-phosphate in islets from ob/ob mice. *Biochem J*. 1991;278(Pt 2):353–9.
66. Khan A, Chandramouli V, Ostenson CG, Berggren PO, Low H, Landau BR, et al. Glucose cycling is markedly enhanced in pancreatic islets of obese hyperglycemic mice. *Endocrinology*. 1990;126(5):2413–6.
67. Jazmin LJ, Young JD. Isotopically nonstationary ¹³C metabolic flux analysis. *Methods Mol Biol*. 2013;985:367–90. doi:10.1007/978-1-62703-299-5_18.
68. Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, O'Brien RM. Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-Phosphatase catalytic subunit-related protein. *J Mol Endocrinol*. 2002;29:205–22.
69. Li X, Shu YH, Xiang AH, Trigo E, Kuusisto J, Hartiala J, et al. Additive effects of genetic variation in *Gck* and *G6pc2* on insulin secretion and fasting glucose. *Diabetes*. 2009;58:2946–53.
70. Rose CS, Grarup N, Krarup NT, Poulsen P, Wegner L, Nielsen T, et al. A variant in the *G6PC2/ABCB11* locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. *Diabetologia*. 2009;52(10):2122–9.
71. Ingelsson E, Langenberg C, Hivert MF, Prokopenko I, Lyssenko V, Dupuis J, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. *Diabetes*. 2010;59(5):1266–75. doi:10.2337/db09-1568.
72. Heni M, Ketterer C, Hart LM, Ranta F, van Haefen TW, Eekhoff EM, et al. The impact of genetic variation in the *G6PC2* gene on insulin secretion depends on glycemia. *J Clin Endocrinol Metab*. 2010;95:E479–84. doi:10.1210/jc.2010-0860.
73. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, et al. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. *PLoS Genet*. 2006;2(5):e81.
74. Merrins MJ, Fendler B, Zhang M, Sherman A, Bertram R, Satin LS. Metabolic oscillations in pancreatic islets depend on the intracellular Ca²⁺ level but not Ca²⁺ oscillations. *Biophys J*. 2010;99(1):76–84. doi:10.1016/j.bpj.2010.04.012.
75. Merrins MJ, Bertram R, Sherman A, Satin LS. Phosphofructo-2-kinase/fructose-2,6-bisphosphatase modulates oscillations of pancreatic islet metabolism. *PLoS One*. 2012;7(4):e34036. doi:10.1371/journal.pone.0034036.
76. Bertram R, Sherman A, Satin LS. Electrical bursting, calcium oscillations, and synchronization of pancreatic islets. *Adv Exp Med Biol*. 2010;654:261–79. doi:10.1007/978-90-481-3271-3_12.
77. Wolf BA, Colca JR, Comens PG, Turk J, McDaniel ML. Glucose 6-phosphate regulates Ca²⁺ steady state in endoplasmic reticulum of islets. A possible link in glucose-induced insulin secretion. *J Biol Chem*. 1986;261(35):16284–7.
78. Jetton TL, Liang Y, Pettepher CC, Zimmerman EC, Cox FG, Horvath K, et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. *J Biol Chem*. 1994;269(5):3641–54.
79. Goh BH, Khan A, Efendic S, Portwood N. Expression of glucose-6-phosphatase system genes in murine cortex and hypothalamus. *Horm Metab Res*. 2006;38(1):1–7.
80. Frigeri C, Martin CC, Svitek CA, Oeser JK, Hutton JC, Gannon M, et al. The Proximal Islet-Specific Glucose-6-Phosphatase Catalytic Subunit Related Protein (IGRP) autoantigen promoter is sufficient to initiate but not maintain transgene expression in mouse islets in vivo. *Diabetes*. 2004;53:1754–64.
81. Wang Y, Flemming BP, Martin CC, Allen SR, Walters J, Oeser JK, et al. Long-range enhancers are required to maintain expression of the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse islets in vivo. *Diabetes*. 2008;57(1):133–41.
82. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. *Philos Trans R Soc Lond B Biol Sci*. 2006;361(1471):1219–35.

83. Barzilai N, Rossetti L. Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin. *J Biol Chem*. 1993;268(33):25019–25.
84. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. *Annu Rev Biochem*. 2012;81:767–93. doi:10.1146/annurev-biochem-072909-095555.
85. Karunakaran U, Park KG. A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. *Diabetes Metab J*. 2013;37(2):106–12. doi:10.4093/dmj.2013.37.2.106.
86. Trinh K, Minassian C, Lange AJ, O'Doherty RM, Newgard CB. Adenovirus-mediated expression of the catalytic subunit of glucose-6-phosphatase in INS-1 cells. Effects on glucose cycling, glucose usage, and insulin secretion. *J Biol Chem*. 1997;272(40):24837–42.
87. Iizuka K, Nakajima H, Ono A, Okita K, Miyazaki J, Miyagawa J, et al. Stable overexpression of the glucose-6-phosphatase catalytic subunit attenuates glucose sensitivity of insulin secretion from a mouse pancreatic beta-cell line. *J Endocrinol*. 2000;164(3):307–14.
88. Wang H, Liu L, Zhao J, Cui G, Chen C, Ding H, et al. Large scale meta-analyses of fasting plasma glucose raising variants in *GCK*, *GCKR*, *MTNR1B* and *G6PC2* and their impacts on type 2 Diabetes Mellitus risk. *PLoS One*. 2013;8(6):e67665. doi:10.1371/journal.pone.0067665.
89. Freathy RM, Hayes MG, Urbanek M, Lowe LP, Lee H, Ackerman C, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in *GCK* and *TCF7L2* are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the International Association of Diabetes and Pregnancy Study Groups. *Diabetes*. 2010;59(10):2682–9. doi:10.2337/db10-0177.
90. Bouatia-Naji N, Bonnefond A, Baerenwald DA, Marchand M, Bugliani M, Marchetti P, et al. Genetic and functional assessment of the role of the rs13431652-A and rs573225-A alleles in the *G6PC2* promoter that strongly associate with elevated fasting glucose levels. *Diabetes*. 2010;59(10):2662–71. doi:10.2337/db10-0389.
91. Sharp PA. Split genes and RNA splicing. *Cell*. 1994;77(6):805–15.
92. Solis AS, Shariat N, Patton JG. Splicing fidelity, enhancers, and disease. *Front Biosci*. 2008;13:1926–42.
93. Dos Santos C, Bougneres P, Fradin D. An SNP in a methylatable *Foxa2* binding site of the *G6PC2* promoter is associated with insulin secretion in vivo and increased promoter activity in vitro. *Diabetes*. 2009;58:489–92.
94. Dai C, Brissova M, Hang Y, Thompson C, Poffenberger G, Shostak A, et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. *Diabetologia*. 2012;55(3):707–18. doi:10.1007/s00125-011-2369-0.
95. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. *Nat Rev Drug Discov*. 2009;8(5):399–416.
96. Jensen MV, Joseph JW, Ronnebaum SM, Burgess SC, Sherry AD, Newgard CB. Metabolic cycling in control of glucose-stimulated insulin secretion. *Am J Physiol Endocrinol Metab*. 2008;295(6):E1287–97.
97. Chen SY, Pan CJ, Nandigama K, Mansfield BC, Ambudkar SV, Chou JY. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. *Faseb J*. 2008;22:2206–13.
98. Wang H, Iynedjian PB. Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. *Proc Natl Acad Sci U S A*. 1997;94(9):4372–7.
99. Wang H, Iynedjian PB. Acute glucose intolerance in insulinoma cells with unbalanced overexpression of glucokinase. *J Biol Chem*. 1997;272(41):25731–6.